Drugs and Crime in Anchorage, Alaska: A Note

Also published in Alaska Justice Forum 22(1): 7 (Spring 2005).This research note examines the relationship between drug use and offense charged through data collected in 2003 from 259 recent arrestees in Anchorage, Alaska using the Arrestee Drug Abuse Monitoring (ADAM) protocol. The analysis is restricted to examining those ADAM participants who tested positive for marijuana and cocaine use.Research note supported in part by Grant No. 2002-BJ-CX-K018 from the Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice

Seasonal Use of Marijuana and Cocaine by Arrestees in Anchorage, Alaska

Previously presented at the Western Society of Criminology, Honolulu, HI, Feb 2005.This paper explores the relation between season (fall, winter, spring and summer) and drug use among arrestees. The analysis examines seasonal differences of proportions of drug tests positive for marijuana or cocaine among recently arrested and booked suspects in Anchorage, Alaska. The study is based on Arrestee Drug Abuse Monitoring (ADAM) data collected in Anchorage during the period between 1999 and the third quarter of 2003.Paper supported in part by Grant No. 2002-BJ-CX-K018 from the Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice.Abstract / Seasonal Use of Drugs / Data and Methods of Analysis / Seasonality and Marijuana Use / Seasonality and Cocaine Use / Discussion / Reference

Hypertension as an Underlying Factor in Heart Failure With Preserved Ejection Fraction

The unique pathophysiology of heart failure with a preserved ejection fraction (HF-PEF) and the involvement of hypertension in its development are only poorly understood. The upregulation of the renin-angiotensin-aldosterone system (RAAS) has been identified as a key pathologic pathway contributing to fibrosis, cardiomyocyte abnormalities, inflammation, and endothelial dysfunction, all of which have been implicated in the progression of hypertension to HF-PEF. In addition, pharmacologic inhibition of the RAAS has been shown in animal models of diastolic dysfunction and in clinical trials to reduce these deleterious processes and to improve diastolic function. Despite these data, clinical trials performed with RAAS inhibitors in patients with HF-PEF have failed to demonstrate morbidity and mortality benefits. To date, there is no proven effective therapy specifically for HF-PEF. The deleterious effects of hypertension on mechanisms underlying the development of HF-PEF underscore the importance of effective and early control of hypertension for the prevention of HF-PEF

Atlas of Anchorage Community Indicators

The Anchorage Community Indicators (ACI) project is designed to make information (extracted from data) accessible so that conversations about the health and well-being of Anchorage may become more completely informed. Policy makers, social commentators, service delivery systems, and scholars often stake out positions based on anecdotal evidence or hunches when, in many instances, solid, empirical evidence could be compiled to support or challenge these opinions.The Atlas of Anchorage Community Indicators makes empirical information about neighborhoods widely accessible to many different audiences. The initial selection of indicators for presentation in the Atlas was inspired by Peter Blau and his interest in measures of heterogeneity (diversity) and inequality and by the work of the Project on Human Development in Chicago Neighborhoods. In both cases the measures they developed were well-conceptualized and validated. The Atlas presents community indicators at the census block group level derived from data captured in the 2000 U.S. Census and the 2005 Anchorage Community Survey. All maps in the Atlas are overlaid by Community Council boundaries to facilitate comparisons across maps.Introduction / COMMUNITY COUNCIL BOUNDARY MAPS / Eagle River Community Councils / North Anchorage Community Councils / South Anchorage Community Councils / Girdwood Community Councils / CENSUS-DERIVES INDICATORS AT BLOCK GROUP LEVEL / 1. Concentrated Affluence / 2. Concentrated Disadvantage / 3. Housing Density / 4. Immigrant Concentration / 5. Index of Concentration at Extremes / 6. Industrial Heterogeneity / 7. Multiform Disadvantage / 8. Occupational Heterogeneity / 9. Population Density / 10. Racial Heterogeneity / 11. Ratio of Adults to Children / 12. Residential Stability / 13. Income Inequality // APPENDIX: ACI Technical Report: Initial Measures Derived from Censu

Is Strategy Different for Very Small and New Firms?

In this paper, we argue that much of the small business strategic management literature has drawn too heavily from work done on large, established firms. We build upon the notions of the liabilities of smallness and newness to discuss how microenterprises and very new firms are different in regards to their strategic analysis, strategic content, strategic resources, and strategic processes. We note that there are a number of important and non-obvious questions that need to be asked that have implications for the most common firms in the world, those that are very small

The strategic management of high-growth firms:a review and theoretical conceptualization

Scholars' knowledge of the factors behind high-growth firms remains fragmented. This paper provides a systematic review of the empirical literature concerning high-growth firms with a focus on the strategic aspects contributing to growth. Based on our review of 39 articles, we identify five drivers of high growth: human capital, strategy, human resource management, innovation, and capabilities. These drivers are combined to develop a conceptual model of high-growth firms that includes potential contingency factors among the five drivers. We also propose a research agenda to deepen the study of high-growth firms in strategic management

Heart Failure in Older Persons: Considerations For The Primary Care Physician

Heart failure (HF) affects over 500,000 Canadians, with 50,000 new patients diagnosed each year. While mortality from cardiovascular diseases has progressively declined in Canada, the burden of HF is expected to continue rising as a result of population aging and improved survival of patients with other cardiovascular diseases. HF is the leading cause of hospitalization and death among those aged 65 years and over, with a mortality rate of up to 50% within 5 years of diagnosis. Elderly HF patients are complex: a recent Ontario study of home care recipients with HF found that these clients had more health instability, took more medications, and had more co-morbidities compared with other home care clients. Optimal management of HF in “complex seniors” requires that clinicians understand the interactions between HF and age-associated syndromes such as frailty, cognitive impairment, and functional decline. As the majority of Canadian patients with HF are treated by primary care providers (PCPs), this article is directed at PCPs caring for older adults with HF. It is meant as a brief overview and discusses how the Canadian Cardiovascular Society (CCS) Consensus Guidelines on HF can be applied in daily practice

Heart failure and cognitive impairment: Challenges and opportunities

As populations age, heart failure (HF) is becoming increasingly common, and in addition to a high burden of morbidity and mortality, HF has an enormous financial impact. Though disproportionately affected by HF, the elderly are less likely to receive recommended therapies, in part because clinical trials of HF therapy have ignored outcomes of importance to this population, including impaired cognitive function (ICF). HF is associated with ICF, manifested primarily as delirium in hospitalized patients, or as mild cognitive impairment or dementia in otherwise stable outpatients. This association is likely the result of shared risk factors, as well as perfusion and rheological abnormalities that occur in patients with HF. Evidence suggests that these abnormalities may be partially reversible with standard HF therapy. The clinical consequences of ICF in HF patients are significant. Clinicians should consider becoming familiar with screening instruments for ICF, including delirium and dementia, in order to identify patients at risk of nonadherence to HF therapy and related adverse consequences. Preliminary evidence suggests that optimal HF therapy in elderly patients may preserve or even improve cognitive function, though the impact on related outcomes remains to be determined

The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design

Background: Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations. Methods and Results: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion criteria are age ≥60 years, heart failure symptoms, an ejection fraction ≥45%, and either hospitalization for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic heart failure. Additional secondary end points include cardiovascular mortality, cause-specific mortality and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Substudies will evaluate changes in echocardiographic measurements and serum collagen markers. Conclusion: I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan

The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design

Background: Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations. Methods and Results: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion criteria are age ≥60 years, heart failure symptoms, an ejection fraction ≥45%, and either hospitalization for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic heart failure. Additional secondary end points include cardiovascular mortality, cause-specific mortality and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Substudies will evaluate changes in echocardiographic measurements and serum collagen markers. Conclusion: I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan